Navigation Links
Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
Date:12/5/2007

.com.

Nastech Forward Looking Statements

Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech to obtain additional funding; (ii) the ability of Nastech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) Nastech's and/or a partner's ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) Nastech's and/or a partner's ability to obtain required governmental approvals; and (v) Nastech's and/or a partner's ability to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Nastech

assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Contacts:

Nastech

Ed Bell

Director, Investor Relations

(425) 908-3639

ir@nastech.com

Russo Partners, LLC

David Schull (Media)

(212) 845-4271


'/>"/>
SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nastech to Host 2007 Analyst and Institutional Investor Day
2. Nastech to Release Third Quarter Financial Results and Host Webcast on Monday, October 29, 2007
3. Nastech Announces Third Quarter 2007 Financial Results
4. Nastech to Present at Acumen BioFin Rodman & Renshaw Healthcare Conference
5. Nastech to Present at BMO Capital Markets Focus on Healthcare Conference
6. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
7. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
8. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
9. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
10. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
11. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... 02, 2015 , ... Genedata, a leading provider of advanced ... Screener ® version 13.0 at ELRIG Drug Discovery 2015. This latest version of ... of new capabilities. Screener now supports High Throughput Flow Cytometry (HT-Flow) and Drug ...
(Date:9/1/2015)... The American Brain Tumor Association (ABTA) is ... Research Grant program. LOIs are due no later than ... Discovery Grants are one-year, $50,000 grants that fund ... current diagnostic or treatment paradigms for adults and children ... at its earliest stages, in the hopes that it ...
(Date:9/1/2015)... (PRWEB) , ... September 01, ... ... the launch of the new ImageXpress® Micro Confocal High-Content Imaging System. This ... emerging assays that use 3D cellular models such as spheroids, tissues, and ...
(Date:9/1/2015)... ... September 01, 2015 , ... VetStem Biopharma announces new Clinical ... joint problems can be caused by injuries and abnormalities of the cervical spine. ... or of the spinal cord itself. This can manifest itself as any or ...
Breaking Biology Technology:New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2ImageXpress Micro Confocal High-Content Imaging System Expands the Boundaries of Research 2ImageXpress Micro Confocal High-Content Imaging System Expands the Boundaries of Research 3VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3
... PARK, N.C., Feb. 16, 2011 Chimerix, Inc., a ... that it has been awarded a contract by the ... advanced development of Chimerix,s broad spectrum antiviral drug candidate, ... a smallpox release. CMX001 is a ...
... DIEGO, Feb. 16, 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: ... a public offering of 6,900,000 shares of its common ... exercise of an overallotment option previously granted to the ... price of $11.25 per share, resulting in aggregate gross ...
... Stryker Corporation,s Orthopaedics division today announced at the ... the findings of the National Joint Registry for ... Cup, Accolade® Hip Stem and Triathlon® Knee System ... rates for the most frequently used brands.(1,2,3) ...
Cached Biology Technology:Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 2Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 3Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 4Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock 2Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock 3Stryker Knee and Hip Implants Demonstrate Lowest Revision Rates, According to the National Joint Registry for England and Wales 2Stryker Knee and Hip Implants Demonstrate Lowest Revision Rates, According to the National Joint Registry for England and Wales 3Stryker Knee and Hip Implants Demonstrate Lowest Revision Rates, According to the National Joint Registry for England and Wales 4
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/6/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced collaboration with Microsoft on biometric fingerprint ... leveraged Synaptics, deep expertise in human interface which ... Through stringent testing, Synaptics, advanced image sensing ... Precision TouchPad (PTP) specification empowering OEMs with Windows ...
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... Miami,s Rosenstiel School of Marine and Atmospheric Science ... Jimenez, Ph.D., as recipient of the 2010 Rosenstiel ... and Fellow of the Cooperative Institute for Research ... of Colorado, his work applies groundbreaking measurement techniques ...
... National Science Foundation has bestowed a Faculty Early Career ... a molecular biologist and geneticist whose work since she ... both her passion for research and her commitment to ... CAREER Award is an exceptional recognition of exceptional qualities ...
... than 40 years ago, Galenia pubescens , an exotic ... altered coastal environments in the south of Spain. Since its ... has studied its invasive capacity. The conclusions of this study ... incipient levels, effective control is needed to prevent this "potentially" ...
Cached Biology News:Dr. Jose L. Jimenez to receive 2010 UM Rosenstiel Award 2FSU biologist wins $1M Early Career Award from National Science Foundation 2FSU biologist wins $1M Early Career Award from National Science Foundation 3Exotic plant takes over dunes of Southern Spain 2
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
Mouse monoclonal antibody raised against a partial recombinant EOMES. NCBI Entrez Gene ID = EOMES...
...
... 2-D Sample Preparation for Membrane Proteins ... 25 membrane,protein extracts for 2-D gel analysis ... Protein Extraction Kit , (contains ... with a packed cell weight of 10 ...
Biology Products: